Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Ann Surg Oncol. 2022 Aug;29(8):4962-4974. doi: 10.1245/s10434-022-11579-0. Epub 2022 Apr 3.
Liver metastasis (LM) after pancreatic ductal adenocarcinoma (PDAC) resection is common but difficult to predict and has grave prognosis. We combined preoperative clinicopathological variables and quantitative analysis of computed tomography (CT) imaging to predict early LM.
We retrospectively evaluated patients with PDAC submitted to resection between 2005 and 2014 and identified clinicopathological variables associated with early LM. We performed liver radiomic analysis on preoperative contrast-enhanced CT scans and developed a logistic regression classifier to predict early LM (< 6 months).
In 688 resected PDAC patients, there were 516 recurrences (75%). The cumulative incidence of LM at 5 years was 41%, and patients who developed LM first (n = 194) had the lowest 1-year overall survival (OS) (34%), compared with 322 patients who developed extrahepatic recurrence first (61%). Independent predictors of time to LM included poor tumor differentiation (hazard ratio (HR) = 2.30; P < 0.001), large tumor size (HR = 1.17 per 2-cm increase; P = 0.048), lymphovascular invasion (HR = 1.50; P = 0.015), and liver Fibrosis-4 score (HR = 0.89 per 1-unit increase; P = 0.029) on multivariate analysis. A model using radiomic variables that reflect hepatic parenchymal heterogeneity identified patients at risk for early LM with an area under the receiver operating characteristic curve (AUC) of 0.71; the performance of the model was improved by incorporating preoperative clinicopathological variables (tumor size and differentiation status; AUC = 0.74, negative predictive value (NPV) = 0.86).
We confirm the adverse survival impact of early LM after resection of PDAC. We further show that a model using radiomic data from preoperative imaging combined with tumor-related variables has great potential for identifying patients at high risk for LM and may help guide treatment selection.
胰腺导管腺癌(PDAC)切除术后肝转移(LM)较为常见,但难以预测,且预后较差。我们结合术前临床病理变量和 CT 影像学定量分析来预测早期 LM。
我们回顾性评估了 2005 年至 2014 年间接受 PDAC 切除术的患者,并确定了与早期 LM 相关的临床病理变量。我们对术前增强 CT 扫描进行肝脏放射组学分析,并开发了逻辑回归分类器来预测早期 LM(<6 个月)。
在 688 例接受 PDAC 切除术的患者中,有 516 例(75%)发生复发。5 年 LM 累积发生率为 41%,且首先发生 LM 的患者(n=194)1 年总生存率(OS)最低(34%),而首先发生肝外复发的患者(n=322)为 61%。LM 时间的独立预测因素包括肿瘤分化差(风险比(HR)=2.30;P<0.001)、肿瘤较大(每增加 2cm,HR=1.17;P=0.048)、血管淋巴管侵犯(HR=1.50;P=0.015)和肝脏纤维化-4 评分(HR=每增加 1 个单位增加 0.89;P=0.029)。使用反映肝实质异质性的放射组学变量的模型可识别出早期 LM 风险患者的受试者工作特征曲线(ROC)下面积(AUC)为 0.71;通过纳入术前临床病理变量(肿瘤大小和分化状态;AUC=0.74,阴性预测值(NPV)=0.86),该模型的性能得到了提高。
我们证实了 PDAC 切除术后早期 LM 对生存的不良影响。我们进一步表明,使用术前影像学放射组学数据结合肿瘤相关变量的模型具有识别高 LM 风险患者的巨大潜力,可能有助于指导治疗选择。